BioCardia, Inc. BCDA
Set alert
At close · Oct 30
After hours · Oct 30, 5:45 PM ET
- YTD
- -31.12%
- 1 year
- -31.67%
- Open
- 0.92
- Prev close
- 0.926
- Mkt cap
- 13.03M
- Vol
- 79.32K
- Avg vol
- 243.28K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.861
- High
- 0.92
- Forward P/E
- -1.57
- Beta
- 1.27
- Short ratio
- 1.41
- Inst. own
- 2.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.28
- 200-d avg
- 3.62
- 1y target
- 25.00
News
-
1 week ago benzinga.com
BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its…
1 week ago globenewswire.com
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
3 weeks ago globenewswire.com
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
-
1 month ago benzinga.com
BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised…
1 month ago globenewswire.com
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
-
1 month ago benzinga.com
BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term…
1 month ago globenewswire.com
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
1 month ago benzinga.com
BioCardia Shares Fall 10% After Hours: Here's Why
BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday's after-market session. The market value of their outstanding shares is at $8.3 million. Alaunos…
1 month ago globenewswire.com
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%…
2 months ago globenewswire.com
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
2 months ago seekingalpha.com
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
BioCardia Q2 EPS $(0.13) Beats $(0.18) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 67.5 percent increase over losses of $(0.40)…
2 months ago globenewswire.com
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,…
3 months ago zacks.com
New Strong Sell Stocks for July 28th
LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million. Catheter Precision…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session. The market value of their outstanding shares is at $10.5 million. Catheter Precision (AMEX:VTAK) stock…
3 months ago zacks.com
New Strong Sell Stocks for July 14th
AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.
-
4 months ago benzinga.com
BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US
Dear Fellow Shareholders,Upon completion of our recent capital raise, I am providing this update on our strategy, top priorities, and business development opportunities to ensure understanding and…
4 months ago globenewswire.com
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
4 months ago benzinga.com
What's Going On With BioCardia Stock Tuesday?
BioCardia (BCDA) stock slides after a $4.4M share dilution, but analysts spot massive upside. Check out the vital levels to watch.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $25 price target.
-
4 months ago benzinga.com
BioCardia Sells 3,509,604 Shares At Average Price Of $1.279 On June 5; No Warrants Issued In Capital Raise
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full…
4 months ago globenewswire.com
BioCardia Announces $4.4 Million Financing
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
4 months ago benzinga.com
Why Is BioCardia Stock Gaining Friday?
BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward potential market approval for its CardiAMP cell therapy.
4 months ago benzinga.com
Why Is BioCardia Stock Gaining Friday?
BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 resistance? Get the technical outlook.
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
4 months ago benzinga.com
BioCardia Receives FDA Confirmation For Its Biologics Evaluation And Research On CardiAMP Cell Therapy System To Treat Ischemic Heart Failure Of Reduced Ejection Fraction
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its…
4 months ago globenewswire.com
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
-
5 months ago benzinga.com
BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes
Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major…
5 months ago globenewswire.com
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory…
5 months ago seekingalpha.com
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
5 months ago benzinga.com
BioCardia Q1 2026 Earnings Call: Complete Transcript
BioCardia Q1 2026 Earnings Call: Complete Transcript
-
5 months ago benzinga.com
BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 64.41 percent increase over losses of $(0.59)…
5 months ago globenewswire.com
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
5 months ago globenewswire.com
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
SUNNYVALE, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,…
-
5 months ago benzinga.com
BioCardia Says FDA Raised No Safety Concerns, Outlines Two Clearance Pathways For Helix Catheter System
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the outcome of its Pre-Submission…
5 months ago globenewswire.com
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
SUNNYVALE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
-
7 months ago benzinga.com
BioCardia Files Request For FDA Meeting Related To Approval For CardiAMP System For Ischemic Chronic Heart Failure
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
7 months ago benzinga.com
BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.17) by 64.71 percent. This is a 76 percent increase over losses of $(0.25) per…
-
7 months ago benzinga.com
Earnings Scheduled For March 24, 2026
Earnings Scheduled For March 24, 2026
-
7 months ago benzinga.com
The FDA Accepts Biocardia's Pre-submission Package For The Approval Of Its Helix Transendocardial Delivery Catheter Intended For Intramyocardial Therapeutic And Diagnostic Agent Delivery
BioCardia has had preliminary meetings with both FDA Center for Devices and Radiological Health (CDRH) and FDA Center for Biological Evaluation and Research (CBER) on this submission in recent weeks.…
-
8 months ago benzinga.com
BioCardia Completes Pre-Submission To FDA Under Q-Submission Program For Approval Of Helix Transendocardial Delivery Catheter For Intramyocardial Therapeutic And Diagnostic Agent Delivery
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
10 months ago benzinga.com
BioCardia Completes Third Preliminary Clinical Consultation With Japan's PMDA On CardiAMP Cell Therapy Intended For Treatment Of HFrEF
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary…
-
11 months ago benzinga.com
BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 60.66 percent increase over losses of $(0.61) per…